KYTX – kyverna therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kyverna Therapeutics (KYTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis [Seeking Alpha]
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample [Seeking Alpha]
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Form 8-K Kyverna Therapeutics, For: Apr 22
Form 8-K Kyverna Therapeutics, For: Apr 21
Form 8-K Kyverna Therapeutics, For: Apr 20
Form 144 Kyverna Therapeutics, Filed by: Walker Karen Marie
Form 144 Kyverna Therapeutics, Filed by: Walker Karen Marie
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.